Educated Patient® Gynecologic Cancers Summit

Several drug classes, including immunotherapy, antibody-drug conjugates and PARP inhibitors have helped improve outcomes for gynecologic cancers.

As part of the CURE® Educated Patient® Gynecologic Cancers Summit, an expert explained the basics of biomarkers and the questions they raise.

Patients can benefit from clinical trials in gynecologic cancers, and knowing that they can advocate for themselves for potential consideration for study enrollment.

Surgery for gynecologic cancers is a common form of treatment, but each surgical approach has its advantages and disadvantages for patients.

After being diagnosed with a type of gynecologic cancer, it is essential for patients to understand the molecular makeup of their disease.